Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Lindholm E) > (2005-2009) > Blood pressure redu...

Details
MARC

Devereux, R. B. (author)

Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy

Article/chapterEnglish2007

Publisher, publication year, extent ...

Taylor & Francis,2007

Numbers

LIBRIS-ID:oai:gup.ub.gu.se/55715
https://gup.ub.gu.se/publication/55715URI
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-6934URI
https://doi.org/10.1185/030079906X162854DOI
http://kipublications.ki.se/Default.aspx?queryparsed=id:12133417URI

Supplementary language notes

Language:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

OBJECTIVE: To compare blood pressure response and antihypertensive medication use visit-by-visit from baseline in patients receiving losartan-based or atenolol-based therapy in the LIFE study. RESEARCH DESIGN: LIFE was a randomized, double-blind trial comparing losartan-based and atenolol-based treatment regimens on the primary composite endpoint of death, myocardial infarction (MI), or stroke in 9193 patients aged 55-80 years with hypertension and left ventricular hypertrophy. Systolic and diastolic, pulse, and mean arterial pressures, blood pressure responder rates, distribution of open-label antihypertensive agents utilized, and the proportion of patients on randomized treatment were determined for each group at each clinic visit over a follow-up period of at least 4 years. RESULTS: Overall blood pressure reductions were comparable in the losartan-based and atenolol-based treatment groups. The mean reductions in sitting trough systolic and diastolic blood pressures from baseline to the end of follow-up (or last visit before a primary endpoint event) were 30.2/16.6 mmHg in the losartan group and 29.1/16.8 mmHg in the atenolol group. The time-averaged difference in overall mean arterial pressure was similar between groups. The proportion of patients on individual dose combinations varied visit by visit but was generally comparable between groups. During the entire study, 56% (2579/4605) of losartan-treated patients received at least one dose of the combination of losartan 100 mg plus hydrochlorothiazide 12.5 mg and 51% of atenolol-treated patients received 100 mg of atenolol plus hydrochlorothiazide 12.5 mg at some time during the study. CONCLUSIONS: Differences in blood pressure or distribution of add-on medications between treatment groups were not evident in the LIFE trial and, thus, cannot account for the observed outcome difference in the primary endpoint of risk reduction of the composite of cardiovascular death, stroke and MI favoring losartan.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Kardiologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cardiac and Cardiovascular Systems hsv//eng
Adrenergic beta-Antagonists/pharmacology/therapeutic use
Aged
Aged
80 and over
Angiotensin II Type 1 Receptor Blockers/pharmacology/*therapeutic use
Antihypertensive Agents/pharmacology/*therapeutic use
Atenolol/pharmacology/therapeutic use
Blood Pressure/*drug effects
Diastole/drug effects
Diuretics/pharmacology/therapeutic use
Double-Blind Method
Female
Follow-Up Studies
Humans
Hydrochlorothiazide/pharmacology/therapeutic use
Hypertension/complications/*drug therapy
Hypertrophy
Left Ventricular/*complications
Losartan/pharmacology/*therapeutic use
Male
Middle Aged
Pulse
Systole/drug effects
Treatment Outcome
Adrenergic beta-Antagonists/pharmacology/therapeutic use

Added entries (persons, corporate bodies, meetings, titles ...)

de Faire, U.Karolinska Institutet (author)
Fyhrquist, F. (author)
Harris, K. E. (author)
Ibsen, H. (author)
Kjeldsen, S. E. (author)
Lederballe-Pedersen, O. (author)
Lindholm, Lars HUmeå universitet,Allmänmedicin(Swepub:umu)lali0003 (author)
Nieminen, M. S. (author)
Omvik, P. (author)
Oparil, S. (author)
Wedel, H. (author)
Hille, D. A. (author)
Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine(Swepub:gu)xdahbj (author)
Karolinska InstitutetAllmänmedicin (creator_code:org_t)

Related titles

In:Curr Med Res Opin: Taylor & Francis23:2, s. 259-701473-48770300-7995

Internet link

Find in a library

Curr Med Res Opin (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Devereux, R. B.; de Faire, U.; Fyhrquist, F.; Harris, K. E.; Ibsen, H.; Kjeldsen, S. E.; show more...; Lederballe-Peder ...; Lindholm, Lars H; Nieminen, M. S.; Omvik, P.; Oparil, S.; Wedel, H.; Hille, D. A.; Dahlöf, Björn, 1 ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cardiac and Card ...

Articles in the publication: Curr Med Res Opi ...

By the university: University of Gothenburg; Umeå University; Karolinska Institutet

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se